Which breast cancer treatment plan is right for you?

When you are first diagnosed with breast cancer, your doctor needs to establish if you are at risk for metastasis and your tumor recurring.

Based on your individual risk of recurrence, whether or not your cancer has the potential to spread, Dr. Weintritt will determine the best therapy for you. If you are at low risk for recurrence, hormone therapy alone may be recommended. Conversely, if you are at high risk, a more aggressive treatment may be recommended that may include chemotherapy.

This distinction is crucial for determining the best possible treatment plan specifically for you. Unlike previous generation genomic tests, MammaPrint interrogates all of the critical molecular pathways involved in the breast cancer metastatic cascade. It analyzes 70 critical genes that comprise a definitive gene expression signature.

This FDA-cleared test can help make this vital determination. MammaPrint provides a “Low Risk” or “High Risk” result for every patient tested. With MammaPrint there is no ambiguity about your individual risk, thereby helping you and Dr. Weintritt determine your need for therapy.

Test results are delivered to Dr. Weintritt within 7-10 days from the date of sample submission.

 

For more information visit Agendia.

 

Note: The information on this Web site is provided as general health guidelines and may not be applicable to your particular health condition. Your individual health status and any required medical treatments can only be properly addressed by a professional healthcare provider of your choice. Remember: There is no adequate substitution for a personal consultation with your physician. Neither the National Breast Center, or any of their affiliates, nor any contributors shall have any liability for the content or any errors or omissions in the information provided by this Web site.

The information, content and artwork provided by this Web site is intended for non-commercial use by the reader. The reader is permitted to make one copy of the information displayed for his/her own non-commercial use.